Analyst Price Target is $15.00
▲ +527.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $15.00, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 527.62% upside from the last price of $2.39.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Lexicon Pharmaceuticals. This rating has held steady since January 2022, when it changed from a Hold consensus rating.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.